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Abstract
In 2011 a new Investment Framework was proposed that described how the scale-up of key
HIV interventions could dramatically reduce new HIV infections and AIDS-related deaths in
low and middle income countries by 2015. This framework included ambitious coverage
goals for prevention and treatment services for 2015, resulting in a reduction of new HIV
infections by more than half, in line with the goals of the declaration of the UN High Level
Meeting in June 2011. However, the approach suggested a leveling in the number of new
infections at about 1 million annually—far from the UNAIDS goal of ending AIDS by 2030. In
response, UNAIDS has developed the Fast-Track approach that is intended to provide a
roadmap to the actions required to achieve this goal. The Fast-Track approach is predicated
on a rapid scale-up of focused, effective prevention and treatment services over the next 5
years and then maintaining a high level of programme implementation until 2030. Fast-
Track aims to reduce new infections and AIDS-related deaths by 90% from 2010 to 2030
and proposes a set of biomedical, behavioral and enabling intervention targets for 2020 and
2030 to achieve that goal, including the rapid scale-up initiative for antiretroviral treatment
known as 90-90-90. Compared to a counterfactual scenario of constant coverage for all ser-
vices at early-2015 levels, the Fast-Track approach would avert 18 million HIV infections
and 11 million deaths from 2016 to 2030 globally. This paper describes the analysis that
produced these targets and the estimated resources needed to achieve them in low- and
middle-income countries. It indicates that it is possible to achieve these goals with a signifi-
cant push to achieve rapid scale-up of key interventions between now and 2020. The
annual resources required from all sources would rise to US$7.4Bn in low-income coun-
tries, US$8.2Bn in lower middle-income countries and US$10.5Bn in upper-middle-income-
countries by 2020 before declining approximately 9% by 2030.
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Introduction
In 2011 a new Investment Framework for HIV/AIDS was proposed to guide efforts towards
the rational use of resources to confront the AIDS epidemic [1]. The Investment Framework
called for all low- and middle-income countries to focus on a set of Basic Programs of proven
effectiveness; to implement social as well as program enablers, based on country-specific deci-
sions about their implementation; and context-specific linkage of HIV interventions that sup-
port broader development objectives, such as social protection for children, reduction of
gender-based violence, and health system strengthening.
The full implementation of the Investment Framework was expected to avert at least 12.2
million new infections and 7.4 million AIDS-related deaths by 2020, and thus provide a cost-
effective means to achieve the goals of the 2011 United Nations General Assembly Political
Declaration on HIV/AIDS [2] for 2015, such as reducing sexual transmission by 50%, reducing
transmission among those who inject drugs by 50%, and virtual elimination of mother-to-child
transmission according to the maximum expected availability of resources by 2015.
In 2014 an updated analysis was published which extended the time frame to 2050 and
included new prevention approaches: Test and Treat, pre-exposure prophylaxis (PrEP) and
potential AIDS vaccines [3]. That analysis examined the role of these new prevention technol-
ogies in getting to zero new infections. It concluded that new infections could be reduced to
as low as 80,000 per year by 2050 with a more ambitious scale-up than the Investment
Framework.
UNAIDS established a global goal of ending the AIDS epidemic as a public health threat by
2030, consistent with the three zeros vision: zero deaths, zero new infections and zero discrimi-
nation, operationalized as a 90% reduction of annual new HIV infections and AIDS-related
deaths in 2030 compared to 2010. This paper examines what is needed in order to accomplish
those goals with available technology and approaches (prophylactic or therapeutic vaccines are
not included).
Methods
Wemodeled future trends in annual new HIV infections and AIDS-related deaths using the
Goals model, part of the Spectrum software package (version 5.41, available at www.
AvenirHealth.org) [4], and applied an Excel version of the Resource Needs Model [5] to esti-
mate the resources needed for program implementation. Goals is a simulation model that cal-
culates HIV transmission among and between different population risk groups (monogamous
heterosexual couples, those with multiple heterosexual partners, female sex workers and cli-
ents, men who have sex with men (MSM) and people who inject drugs (PWID)) on the basis of
their behaviors (number of partners, contacts per partner, condom use, age at first sex, needle
sharing) and characteristics that influence transmission (presence of other sexual transmitted
infections, stage of infection, male circumcision, and use of antiretroviral therapy (ART) and
PrEP). The effects of the bio-medical interventions are based mostly on results from random-
ized control trials that directly measured the effect on incidence. The effects of the behaviour
change interventions are included both as direct effects on condom use and numbers of part-
ners as well as part of the enabling environment that allows for greater uptake of interventions.
We have included cash transfers for girls as several studies have shown reductions in incidence
or changes towards safer behaviors. But because these effects seem to be limited to locations
where school enrollment rates are low, we have assumed implementation only in countries
with low rates of secondary enrollment for girls [6,7,8]. The coverage targets and the effects of
the interventions are shown in Table 1. Complete details of the model are available elsewhere
[3].
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Table 1. Coverage goals and effects for the interventions included in this analysis.
Intervention 2020 Coverage 2030 Coverage Effects
KEY POPULATIONS
Service package for female sex
workers
90% 90% 90% condom use at last sex act
Service package for MSM 90% 90% 90% condom use at last sex act
Service package for
transgender populations
90% 90% 90% condom use at last sex act
Service package for PWID 90% 90% 90% condom use at last sex act, 51%
reduction in percentage sharing
needles
Opioid substitution therapy for
PWID
40% 40% 46% reduction in number of sexual
partners, 71% reduction in needle
sharing
Service package for prisoners 90% 90% Increased condom use in prisons
BEHAVIOUR CHANGE
INTERVENTIONS
Condom promotion 90% condom use at last sex 90% condom use at last sex 90% condom use at last sex among
people with multiple partners
Cash transfers for girls 30% In Hyper-endemic countries with
low rates of secondary school
enrollment1
50% In Hyper-endemic countries
with low rates of secondary school
enrollment1
40% reduction in incidence among
young women and girls (15–24 years
old) in areas with low rates of
secondary enrollment [6]
MEDICAL INTERVENTIONS
PMTCT 95% 95% 80% starting ART before current
pregnancy, 15% starting during
current pregnancy. 98% reduction in
perinatal transmission, 87% reduction
in transmission during breastfeeding
[9]
Male circumcision 90% of 10–29 year old men in
countries with generalized epidemics
and low MC rate2
90% of 10–29 year old men in
countries with generalized
epidemics and low MC rate2
60% reduction in susceptibility [10,
11, 12]
Post-exposure prophylaxis
(PEP)
80% 80% Provided to rape victims and health
workers experiencing accidental
exposure
PrEP for sero-discordant
couples
10% in generalized and hyper-endemic
countries
30% in generalized and hyper-
endemic countries
80% reduction in susceptibility for
sero-discordant couples. PrEP
includes oral pills, vaginal gel, vaginal
ring and injectable forms. [13, 14, 15,
16]
PrEP for sexually active
females 15–24 in areas with
incidence above 3% in this
population group
10% in hyper-endemic countries 30% in hyper-endemic countries 80% reduction in susceptibility. For
adolescent females we assume half
this effect through 2020 then the full
effect after 2020. PrEP includes oral
pills, vaginal gel, vaginal ring and
injectable forms. [13, 14, 15, 16]
Testing 24% of all adults and children in
countries with generalized epidemics
and of key populations and people with
multiple partners in countries with
concentrated epidemics
Gradual decrease to 20% of key
populations, those with multiple
partners and pregnant women in all
countries with incidence below
0.1%. 20% of adults and children in
countries with incidence above 0.1%
Identify HIV+ for linkage to care
Pre-ART care 81% of PLHIV not on ART 90% of PLHIV not on ART
(Continued)
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We applied the Goals model to 45 countries that together account for 86% of new infections
globally:
• East and Southern Africa: Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique,
Namibia, Rwanda, South Africa, Swaziland, United Republic of Tanzania, Uganda, Zambia,
Zimbabwe
• West and Central Africa: Burkina Faso, Cameroon, Democratic Republic of the Congo,
Ghana, Liberia, Nigeria, Sierra Leone
• Latin America and the Caribbean: Bolivia, Brazil, Costa Rica, Dominican Republic, El Salva-
dor, Guatemala, Haiti, Jamaica, Mexico, Nicaragua, Panama
• Asia and Pacific: Bangladesh, Cambodia, China, India, Indonesia, Pakistan, Thailand, Viet
Nam
• Middle East and North Africa: Egypt, Morocco
• Eastern Europe: Russian Federation, Ukraine
• West and Central Europe and North America: United States of America
Table 1. (Continued)
Intervention 2020 Coverage 2030 Coverage Effects
Adult ART 81% (90% started, 90% retained) 90% (95% started, 95% retained) Eligibility for treatment expands to all
PLHIV by 2018. 95% reduction in
infectiousness among those virally
suppressed [17]. By 2030 AIDS-
specific mortality rates decline by
50% from 2015 rates due to
enhanced retention and viral
suppression.
SOCIAL ENABLERS Includes community mobilization3,
media communications4 and other
general population approaches that
support behavior change
1 Hyper-endemic countries are: Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, Zambia and Zimbabwe.
2 Countries include Botswana, Ethiopia (Gambela only), Kenya (Nyanza only), Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, South
Sudan, Swaziland, United Republic of Tanzania, Uganda, Zambia and Zimbabwe.
3 Community mobilization can be divided into three categories: Outreach and peer communication and engagement activities; support activities; and
advocacy, transparency and accountability. Community mobilization can be supported through community system strengthening which is a systematic
approach to promote the development of informed, capable and coordinated communities and community based organizations. Hallmarks of effective
community system strengthening include the involvement of a broad range of community actors and enabling them to contribute as equal partners
alongside other actors to the long term sustainability of health and other interventions at community level. Community system strengthening aims to
improve health outcomes by developing the role of key affected populations, communities and community based organizations in the design, delivery,
monitoring and evaluation of services, activities and programs.
4 Media communication utilizes one or more channels to transmit a specific message to a large audience. Examples include brochures, billboards,
posters, newspaper or magazine articles, comic books, television, radio, music videos, Internet, cell phones, songs, dramas, traditional and folk media,
and interactive theatre. Media communication includes development of communication messages and materials and their transmission. Media
communication seeks to promote positive changes in cognitive and behavioural outcomes such as increasing knowledge of modes of HIV transmission,
increasing perceived risk of contracting HIV, reducing high-risk sexual behaviours such as having multiple partners, increasing positive protective
behaviours such as condom use, and increasing the utilization of health care services. Media communication can also be utilized to create a supportive
environment and often targets social, cultural and gender norms that may hinder behaviour change.
doi:10.1371/journal.pone.0154893.t001
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The disease progression of the HIV+ population in the model is tracked by CD4 count.
AIDS-related mortality is determined by CD4 count category and ART status and modeled as
a competing risk with mortality from other causes. New child infections due to mother-to-
child transmission are estimated based on the coverage of PMTCT services [9]. Data inputs for
each country were drawn from national surveys and national progress reports (available at
www.unaids.org) and adjusted to match the prevalence trends from national estimates as
reported to UNAIDS. Country-specific coverage rates are based on country reports to UNAIDS
and available at www.aidsinfoonline.org. When country-specific data were not available we
used regional averages. Parameter values for progression and mortality rates are based on rec-
ommendations from the UNAIDS Reference Group on Estimates, Modeling and Projections
[18] and are given in Tables A-I in Supporting Information File (S1 File). The impact results
were adjusted for countries that were not explicitly modeled, so as to represent totals for 163
countries.
The resources required are estimated by intervention and year for each of the 117 low and
middle- income countries (L&MICs). For most interventions the resources are estimated by
multiplying the size of the target population (such as young women and girls, sex workers or
men with multiple partners) by the coverage (the percentage reached with the intervention)
and the unit cost (the cost to provide the service to one person for one year). Demographic
data on the number of people by age and sex in each country are from the United Nations Pop-
ulation Division’s World Population Prospects 2015 [19]. Behavioral data and current coverage
estimates are primarily from country reports as available in the UNAIDS on-line database
‘aidsinfoonline’.
General population interventions (community mobilization, voluntary medical male cir-
cumcision, HIV testing for general population, PrEP for serodiscordant couples) are to be
implemented only in hyper-endemic and generalized epidemic countries. In generalized epi-
demics, incidence may vary substantially by geographic region. In those cases implementation
efficiency was modeled to be improved by focusing the general population interventions on
those areas of highest incidence. We have used survey data to estimate the proportion of the
population living in the geographic areas accounting for at least two-thirds of people living
with HIV. This percentage ranges from 41% and 43% in Kenya and Nigeria to 75% in the Côte
d’Ivoire. For countries without data we used the average of those countries with data, 59%.
Thus, in generalized epidemics the cost of these interventions is reduced by focusing the inter-
ventions in the areas that remain with high incidence. The interventions included, target cover-
age for all low- and middle-income countries and the effects are shown in Table 1. We also
created a counter-factual scenario that assumes that coverage of all interventions remains con-
stant at early-2015 levels through 2030.
Initial estimates of unit costs by intervention and country were based on a review of pub-
lished and unpublished reports. An interactive database of unit costs is available at http://www.
avenirhealth.org/PolicyTools/UC/. HIV Investment Cases conducted over the past 3 years pro-
vided updated information for 22 countries. The country-specific unit costs, current coverage
levels and population size estimates were reviewed and revised as necessary by teams of
national experts from 40 countries at regional meetings in Sub-Saharan Africa, Latin America
and the Caribbean and Asia; a minority of countries did not request an update in the estimates.
The regional average unit costs used in this analysis are shown in Tables 2 and 3.
In addition to the direct intervention costs we also include costs for Program Enablers,
Social Enablers and Development Synergies. Program Enablers include planning and coordina-
tion, administration, supplies and logistics, staff training, M&E including surveillance and
information systems. Social Enablers include communications for public awareness, advocacy
and building political commitment, reform of laws and legal policies, stigma reduction and
Fast-Track to Ending AIDS
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structural interventions. Development Synergies refers to activities wholly or partially sup-
ported by the AIDS budget that support broader development objectives such as support for
orphans and vulnerable children, AIDS education, and prevention of violence against women.
Costs for health system strengthening, while part of synergies, were included as a separate cost
item. Cash transfers also have broader development objectives; as indicated in Table 2, financ-
ing for cash transfers drops from 100% funding under AIDS budgets during 2016–2020 to 30%
by 2030.
Table 2. Regional average costs per person reached (in 2015 USD $).
Intervention Asia and
Pacific
East and
Southern
Africa
Eastern
Europe &
Central Asia
Latin
America
Middle East
North Africa
West and
Central
Africa
West and Central
Europe and North
America
Notes
Key Populations
Service package for
female sex workers
$ 77 $94 $108 $30 $15 $53 $180 1,5
Service package for
MSM
$45 $101 $45 $44 $105 $51 $42 5
Service package for
transgender
populations
$45 $101 $45 $44 $105 $51 $42 5
Service package for
PWID
$162 $135 $123 $49 $69 $90 $113 5
Opioid substitution
therapy for PWID
$363 $265 $664 $664 $236 $265 $1,190 2
Service package for
prisoners
$38 $31 $14 $10 $29 $1 $5
Biomedical
interventions
PMTCT $984 $365 $2,472 $1,967 $274 $585 $2,204 3
Voluntary medical male
circumcision
$85
Post-exposure
prophylaxis
$100 $40 $101 $134 $137 $40 $101
Pre-exposure
prophylaxis
$200 $200 $200 $200 $200 $200 $200
Condom promotion and
supply
$0.12 $0.26 $0.27 $0.31 $0.29 $0.26 $0.27
Behavior change
Cash transfers for girls $240 4
HIV testing services $2 $9 $2 $2 $2 $8 $2
Social enablers
Community mobilization $2 $4 $2 $6 $2 $2 $2
All unit costs are expressed as the annual cost per person reached, except condoms are the cost per condom distributed.
Notes
1. Includes $5.92 for activities to prevent gender-based violence and assumes that 5% of condoms used are female condoms
2. We assume that 100% of costs are funded by AIDS budgets through 2020 declining to 30% by 2030.
3. The costs of PMTCT prophylaxis are shifted to the ART line item as Option B+ expands, leaving 10% of current cost by 2030 to cover the costs of
syrup for the infants and nevirapine for those presenting too late to start ART.
4. 100% funded from AIDS budgets through 2020 declining to 30% by 2030
5. Unit costs decline by 2030 due to economies of scale by 16% for female sex workers, 19% for MSM and transgenders, 8% for PWID
doi:10.1371/journal.pone.0154893.t002
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Analysis and central reviews and revisions of country expenditure data collected through
National AIDS Spending Assessments indicates that Program Enablers add 14% to direct inter-
vention costs, Social Enablers add another 8% and Development Synergies add another 10.7%.
We also included costs of health system strengthening rising from 6.1% of direct costs in 2015
to 9.7% by 2020 to support the rapid expansion required to reach these targets, and then declin-
ing back to 6.1% by 2030.
These projections assume that ART coverage continues the rapid scale up of the past few
years so that the UNAIDS 90-90-90 treatment targets are achieved by 2020 at the same time as
being consistent with WHO guidelines recommending therapy for all people living with HIV.
[20] This means that 90% of all people living with HIV (PLHIV) are aware of their status, 90%
of these are started and retained on ART treatment (together resulting in 81% ART coverage)
and 90% of these achieve viral suppression by 2020. Once these targets are achieved we assume
gradual improvements in service coverage and impact over the next ten year to 95-95-95 by
2030 (resulting in 90% ART coverage by 2030). In our projections all countries start at their
current level of coverage and progress towards these targets by 2020 and 2030.
The effectiveness of ART in preventing transmission and HIV-related mortality is linked to
the proportion of patients that achieve sustainable viral suppression. We assume that those
patients who are virally suppressed do not transmit HIV [17]. The mortality of patients on
ART is based on analysis of patient records by the IeDEA (International Epidemiologic Data-
bases to Evaluate AIDS) Consortium [21]. Our model links viral suppression with both infec-
tiousness and mortality. As a result current mortality rates are reduced by half by 2030 due to
enhanced viral suppression.
Assumptions about the future costs of treatment were based on guidance from a committee
of experts in ART costs (listed in Acknowledgements). The committee suggested that the cost
of first line drugs in sub-Saharan Africa would decline by 55% to $75 by 2020 and that the cost
of second line drugs would decline by 63% to $210 by 2020. For all other regions the same per-
centage decline is applied to current prices. The costs of third line drugs is assumed to be 10
times the cost of first line drugs. The future costs of service delivery and lab costs depends on
the visit schedule. Many programs are making efforts to rationalize visit schedules to reduce
the costs of ART. Based on WHO guidelines and the recommendations of our expert panel we
assumed the following visit and lab schedule by 2020:
• Patients initiating ART: one CD4 test at initiation, 2 viral load tests (VL), four medical con-
sultations, and two drug delivery/adherence support visits in the first year.
Table 3. Current cost per patient per year for ART and pre-ART services. (2015 USD$).
Region Service Delivery Labs ARVs—1st line ARVs—2nd line Pre-ART
Eastern Europe and Central Asia $ 2,130 $ 255 $ 148 $ 684 $ 1,124
East Asia and Pacific $ 109 $ 308 $ 136 $ 547 $ 444
Latin America and Caribbean $ 1,725 $ 207 $ 634 $ 1,250 $ 910
Middle East and North Africa $ 1,198 $ 144 $ 136 $ 328 $ 632
South and South-East Asia $ 27 $ 140 $ 148 $ 400 $ 96
Sub-Saharan Africa $ 222 $ 71 $ 136 $ 332 $ 182
Number of countries which contributed data 17 16 24 15 11
Notes:
These are costs in 2015 or latest year available.
Pre-ART costs largely disappear by 2020 as people would be started on ART as soon as they are identified as living with HIV; costs were kept constant.
doi:10.1371/journal.pone.0154893.t003
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• Stable patients (assumed to be those virally suppressed): one VL test, 2 drug delivery/adher-
ence support visits and 1.2 medical consultations per year.
• Patients not virally suppressed: 2 VL tests, 3 medical consultations and 2 drug delivery/
adherence support visits per year
• HIV+ pregnant women: 6 medical consultations per pregnancy, one blood test, one test for
early infant diagnosis.
We assumed future costs of $9.50 per CD4 test, $26 per viral load test and $20 per EID test.
The costs per visit were calculated as 1/8 of the reported service delivery costs in 2015 (assum-
ing an average of 8 visits per patient). We assume that by 2020, 30% of patient care will be
delivered through community-based personnel at a cost 25% lower than facility-based care.
Finally, we assumed that the percentage of patients on second line would increase to 13.5% by
2020 and the percentage on third line would increase to 3.4%. These assumptions result in the
future costs of treatment shown in Table 4. The difficulties of finding and retaining patients to
achieve 90-90-90 in 2020 are reflected in higher testing costs in 2020. After 2020 there may be
higher marginal costs in 2030 but increasing efficiency of treatment for the existing patient
population could still lead to small declines in average costs.
Results
The scale up in prevention and treatment to the future levels described above would reduce
new HIV infections in low- and middle-income countries from 2.2 million 2010 to about
280,000 by 2030, a reduction of nearly 90%. The number of new child infections decreases a bit
more than the total, by 94%. The number of AIDS-related deaths would also be reduced
sharply from 1.6 million in 2010 to 340,000 by 2030, or a reduction of nearly 80%, as shown in
Fig 1. In both cases the sharpest reduction occurs by 2020 when most of the intervention scale-
up targets are achieved. New infections continue to decline an additional 46% from 2020 to
2030 as a result of high coverage of prevention interventions and continued scale up of ART
resulting in greater viral suppression. AIDS-related deaths stabilize after 2020 due to slower
scale up of ART but eventually drop another 35% from 2020 to 2030. The percentage reduc-
tions are similar across all geographic regions so that by 2030 about 44% of new infections will
be in East and Southern Africa, 12% in West and Central Africa and 16% in Asia and the
Pacific.
Table 4. Future costs of antiretroviral treatment, for different categories of patients, by region.
Region New Patients Stable Patients Patients not Virally Suppressed Pregnant Women (Incremental Costs)
Asia and Pacific 2020: $378 2020: $261 2020: $340 2020: $111
2030: $341 2030: $224 2030: $340 2030: $111
Eastern Europe and Central Asia 2020: $1488 2020: $855 2020: $1268 2020: $627
2030: $1440 2030: $806 2030: $1220 2030: $627
Latin America 2020: $1551 2020: $1059 2020: $1381 2020: $485
2030: $1292 2030: $800 2030: $1220 2030: $485
Middle East and North Africa 2020: $1232 2020: $702 2020: $1049 2020: $524
2030: $1206 2030: $524 2030: $1023 2030: $524
West and Central Africa 2020: $391 2020: $259 2020: $348 2020: $126
2030: $379 2030: $247 2030: $336 2030: $126
East and Southern Africa 2020: $391 2020: $259 2020: $348 2020: $126
2030: $379 2030: $247 2030: $336 2030: $126
doi:10.1371/journal.pone.0154893.t004
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Today about two-thirds of AIDS-related deaths occur to those who are not on ART. By
2030 there would be about an equal number of deaths among those few people who are not on
ART and the much larger number receiving ART.
Fig 1 shows the trend in new HIV infections and AIDS-related deaths for both the Fast-
Track and the counterfactual scenario. The constant coverage assumption in the counterfactual
scenario leads to approximately constant incidence rates in most of the modeled countries
reversing the downward trend of the past several years achieved by improving coverage rates.
The adoption of the Fast-Track approach would result in averting11 million AIDS-related
deaths and 18 million new HIV infections globally during the period 2016–2030; and 9.6 mil-
lion and 15.1 million respectively in L&MICs.
In the countries in East and Southern Africa with high HIV prevalence and low levels of
male circumcision, which account for about half of all new infections, under the Fast-Track
approach 37% of infections averted are due to the use of effective ART, 37% due to condoms
for those with multiple partners and 16% due to VMMC. The rest are averted by programs for
key populations, PrEP and cash transfers. In generalized epidemics with already high levels of
circumcision, 42% of infections averted are due to ART, 36% are due to condoms in multi-part-
ner sex and 13% is due to programs for key populations. In concentrated epidemics, 48% of
infections averted are due to ART, 26% to programs for key populations including PrEP and
18% to condoms for multi-partner sex.
Achieving these results will require significant increases in the number of people reached
with prevention and treatment interventions. The service package for key populations is not
limited to provision of condoms, safe needles or information and education, but also includes
population services for discrimination reduction, promotion of access to testing, treatment and
retention. Coverage of the service package for key populations (sex workers, men who have sex
with men, transgender populations, people who inject drugs, prisoners) would increase by
approximately 75% by 2030, while the number receiving opioid substitution therapy would rise
by 160%. The population receiving cash transfers would rise to 5.5 million and the number
receiving PrEP would rise to 13.5 million, mostly for discordant couples and key populations.
The number of people receiving ART would rise to about 29 million by 2020 and remain at
about that level by 2030. The number of people receiving ART would eventually decline as the
result of fewer new infections, but that decline would occur well after 2030 when those started
on treatment before 2020 reach old age and begin dying from other causes.
Fig 1. Trends in new HIV infections and AIDS-related deaths in low- andmiddle-income countries from 2010–
2030, for the Fast-Track and constant coverage scenarios.
doi:10.1371/journal.pone.0154893.g001
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The costs of achieving these increases in services in L&MICs are shown in Fig 2. These are
estimates for all sources of financing including domestic government expenditures, donor
assistance, private sector and out-of-pocket expenditures. The annual needs reach US$7.4 bil-
lion in Low-income countries, US$8.2 billion in lower middle-income countries and US$10.5
billion in upper-middle-income-countries by 2020 before declining approximately 9% in
L&MICs by 2030. The decline is largely due to reductions in the unit costs of ART, reduced
need for testing, a reduction in the proportion of opioid substitution therapy supported from
the AIDS budget and the reduced need for pre-ART services and PMTCT due to the scale up
of ART. Cumulative resource needs to 2030 are concentrated in a few interventions with two
thirds needed for just 4 interventions: 39% for ART, 10% for program enablers, 9% for services
for key populations and 7% for condoms. The resource needs for the 90/90/90 treatment com-
ponents, including the basic programme components (pre-ART, ART and testing), the respec-
tive programme support costs, the appropriate share of the social enablers and shared costs of
the outreach to key populations account for 78% in 2016, 67% in 2020 and 51% in 2030 in
L&MICs.
Resource needs are concentrated in East and Southern Africa (36%), Asia and the Pacific
(21%), Latin America (17%) and West and Central Africa (16%). Over the entire time period,
27% of resources are needed in low income countries, 30% in lower middle income countries
and 43% in upper middle income countries (Fig 3). Detailed tables showing the resource needs
by country, intervention and year are available in Tables J-AE in the Supporting Information
File (S1 File).
Discussion
This analysis has shown what is required to achieve reductions in new infections and HIV-
related deaths of 80–90% from 2010 to 2030. Achieving those goals will require rapid scale up
Fig 2. Annual Resource Needs by Intervention, 2013–2030. Key: SW = sex workers, MSM =men who have sex with
men, PWID = people who inject drugs, OST = opioid substitution therapy, PMTCT = prevention of mother-to-child
transmission, VMMC = voluntary medical male circumcision, PEP = post-exposure prophylaxis, PrEP = pre-exposure
prophylaxis, Dev. Synergies = Development Synergies
doi:10.1371/journal.pone.0154893.g002
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to near universal coverage of key prevention and treatment interventions in all countries with
large epidemics. Most important will be reaching targets for ART for all, voluntary medical
male circumcision, PrEP, condoms, key populations and PMTCT.
Great progress has been achieved over the past decade. Continued rapid progress in the
near future is dependent on multiple factors, especially increases in resources available for HIV
programs and strengthened health systems to support service delivery.
However, keeping the coverage of the AIDS related services at the 2015 levels would imply
that for many countries, the epidemic would increase. There would be 18 million more new
infections and 11 million more AIDS deaths from 2010 to 2030 compared to achieving the
Fast-Track targets globally.
One key factor for achieving a 90% reduction in new infections by 2030 is the need for a
major effort to reach the target coverage levels between now and 2020. Rapid scale up of testing
and treatment programs during this period will create the conditions to achieve the 90% reduc-
tion in new infections by 2030. A 10-year delay in reaching the 2020 targets would result in 3.2
million additional AIDS deaths and 6 million additional new infections in the 2016–2030
period.
Another key factor needed to generate the resources needed will be demonstrating that they
are used effectively. We will need even greater efforts to improve cost-effectiveness by: i) target-
ing efforts to the geographic areas where they will have the greatest impact, ii) understanding
the cost components of individual interventions and using that information to improve cost-
effectiveness, iii) ensuring the right mix of interventions for the epidemic structure in each
location, iv) continuing cooperation with manufacturers to ensure that prices for key ARVs
and diagnostics are affordable to all, v) understanding costs at the facility level and above in
order to optimize the mix of facilities providing key services, and vi) by adopting streamlined
models of care without compromising the quality of services.
It should be noted that there are significant uncertainties in these projections. Although
there is some uncertainty about the effectiveness of each of the interventions, the major source
Fig 3. Resources available in 2014 and resources required from 2015–2030 by level of income in low-
andmiddle-income countries (according to 2015WB income level classification).
doi:10.1371/journal.pone.0154893.g003
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of uncertainty is whether programs can be scaled up as envisioned here. We did not include
completely new interventions, such as prophylactic or therapeutic vaccines, that do not cur-
rently exist but could potentially make a contribution by 2030. We have limited the coverage of
PrEP to 10% in 2020 and 30% in 2030 because of uncertainties about how quickly it can be
implemented while addressing issues of adherence and costs. There is certainly the potential
for future PrEP formulations with improved adherence and lower cost which could play a
much larger role in achieving the desired reductions in incidence. Scaling up ART to the 90-
90-90 targets by 2020 will require major efforts on the part of national programs, attention to
human rights, expanded testing, improved adherence and retention, and a 50% increase in
resources for treatment and testing. The significant contribution of voluntary medical male cir-
cumcision can only occur if programs become more effective at generating demand. Delays in
achieving any of these targets will similarly delay the time by which these goals are achieved to
well past 2030.
Today, two-thirds of all new infections occur in just 12 countries: South Africa, Nigeria,
Russian Federation, Uganda, Mozambique, India, Indonesia, Zimbabwe, Kenya, Zambia,
China and United Republic of Tanzania. Achieving these global impacts will require significant
progress in each of these countries.
This analysis provides a roadmap for what is needed to end the AIDS epidemic as a global
public health threat within the next 15 years as expressed in the Sustainable Development Goal
3.3 [22]. There are significant challenges ahead that must be addressed, but now we need to
find the resources, the will, the human resources, the health and community systems and effec-
tive implementation approaches to make this a reality.
Current investments in the AIDS response are estimated at US$ 19.2 billion per year for the
countries classified as low and middle-income countries in 2014, excluding the countries that
have progressed to the high income category per the World Bank classification of countries.
The resource needs for research and development are not included in these estimates. Com-
pared to 2014 levels, an additional sum of US$6 billion in 2020 and US$ 2.9 billion in 2030 is
needed. While these are large amounts, they are small compared to the amounts of public
spending that countries devote to health.
In 2012, low- and middle-income countries spent more than USD$1.1 trillion on health
from domestic resources. Projections of health expenditures per capita, regardless of the
source, indicate that if the Fast-Track approach were fully funded, the HIV investment
(adjusted to the health components) would be less than 4% of the total health expenditures in
low income-countries, and less than 1% in lower-middle- and in upper-middle income- coun-
tries by 2020; by 2030 these percentages would decline to less than 1% in low-income countries,
and less than a quarter of a percentage point in lower- and upper-middle-income countries
respectively.
Providing the resource needs for critical enablers allows the full implementation of the criti-
cal basic programmes. For example, programme enablers include components that support the
treatment programme, e.g. a functional supply chain of commodities (anti-retroviral medicine,
testing kits, condoms, etc), quality assurance, training, and strategic information. Social pro-
gramme enablers include community mobilization that includes the promotion of access to
testing for key populations, as well as for young women and girls and broader population seg-
ments in countries with high HIV incidence or prevalence; in addition, community mobilisa-
tion includes support for adherence for ART services and for preventive services tailored
according to the needs of specific population groups.
The frontloading of the resources needed to scale up the response by 2020 will be challeng-
ing. But this global effort will allow us to achieve the end of the AIDS epidemic as a global
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public health threat by 2030. There are few investments in global development that would have
such a profound impact.
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